Edward L. Korn

Best Publications

• Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

  Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman

  822
  Citations

• Epidemiologic studies utilizing surveys: accounting for the sampling design.

  Unknown

  513
  Citations

• Randomized Clinical Trials With Biomarkers: Design Issues

  Boris Freidlin;Lisa M. McShane;Edward L. Korn

  478
  Citations

• Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

  Lawrence V. Rubinstein;Edward L. Korn;Boris Freidlin;Sally Hunsberger

  443
  Citations

• Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

  Edward L. Korn;Susan G. Arbuck;James M. Pluda;Richard Simon

  396
  Citations

• A comparison of two phase I trial designs.

  Edward L. Korn;Douglas Midthune;T. Timothy Chen;Lawrence V. Rubinstein

  381
  Citations

• Controlling the number of false discoveries: application to high-dimensional genomic data

  Edward L Korn;James F Troendle;Lisa M McShane;Richard Simon

  366
  Citations

• Examples of Differing Weighted and Unweighted Estimates from a Sample Survey

  Edward L. Korn;Barry I. Graubard

  278
  Citations

• Methods for analyzing panel studies of acute health effects of air pollution.

  Edward L. Korn;Alice S. Whittemore

  263
  Citations

• Outcome-Adaptive Randomization: Is It Useful?

  Edward L. Korn;Boris Freidlin

  263
  Citations

• Measures of explained variation for survival data.

  Edward L. Korn;Richard Simon

  249
  Citations

• Censoring distributions as a measure of follow-up in survival analysis.

  Edward L. Korn

  230
  Citations

• Simultaneous Testing of Regression Coefficients with Complex Survey Data: Use of Bonferroni t Statistics

  Edward L. Korn;Barry I. Graubard

  217
  Citations

• Biomarker enrichment strategies: matching trial design to biomarker credentials

  Boris Freidlin;Edward L. Korn

  209
  Citations

• Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

  Lori E. Dodd;Edward L. Korn;Boris Freidlin;C. Carl Jaffe

  203
  Citations

• APPLICATIONS OF CRUDE INCIDENCE CURVES

  Edward L. Korn;Frederick J. Dorey

  185
  Citations

• Multi-Arm Clinical Trials of New Agents: Some Design Considerations

  Boris Freidlin;Edward L. Korn;Robert Gray;Alison Martin

  184
  Citations

• Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers

  Mei Yin C. Polley;Boris Freidlin;Edward L. Korn;Barbara A. Conley

  183
  Citations

• Analysis of Large Health Surveys: Accounting for the Sampling Design

  Edward L. Korn;Barry I. Graubard

  179
  Citations

• Choice of column scores for testing independence in ordered 2 X K contingency tables.

  Barry I. Graubard;Edward L. Korn

  177
  Citations